{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PLACEBO&page=31",
    "query": {
      "intervention": "PLACEBO",
      "page": 31
    },
    "page_size": 10
  },
  "pagination": {
    "page": 31,
    "page_size": 10,
    "total_count": 33093,
    "total_pages": 3310,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PLACEBO&page=32&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PLACEBO&page=30&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T09:23:26.259Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04166552",
      "title": "Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Cutaneous Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "Patients will be randomized to receive EHP-101 or Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emerald Health Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 36,
      "start_date": "2020-06-11",
      "completion_date": "2024-10",
      "has_results": false,
      "last_update_posted_date": "2023-09-21",
      "last_synced_at": "2026-10-24T09:23:26.259Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Huntington Beach, California • Los Angeles, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04166552"
    },
    {
      "nct_id": "NCT01725152",
      "title": "Ganaxolone Treatment in Children With Fragile X Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fragile x Syndrome"
      ],
      "interventions": [
        {
          "name": "Ganaxolone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Marinus Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 59,
      "start_date": "2012-11",
      "completion_date": "2016-11-01",
      "has_results": true,
      "last_update_posted_date": "2023-04-10",
      "last_synced_at": "2026-10-24T09:23:26.259Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01725152"
    },
    {
      "nct_id": "NCT03564158",
      "title": "Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "meropenem-vaborbactam",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 53,
      "start_date": "2018-05-01",
      "completion_date": "2018-11-19",
      "has_results": false,
      "last_update_posted_date": "2019-01-10",
      "last_synced_at": "2026-10-24T09:23:26.259Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03564158"
    },
    {
      "nct_id": "NCT06141447",
      "title": "Changes in Hemorrhage With Prophylactic Oxytocin for Dilation and Evacuation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemorrhage"
      ],
      "interventions": [
        {
          "name": "Oxytocin + normal saline",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 55 Years · Female only"
      },
      "enrollment_count": 150,
      "start_date": "2024-05-02",
      "completion_date": "2026-11-02",
      "has_results": false,
      "last_update_posted_date": "2024-12-10",
      "last_synced_at": "2026-10-24T09:23:26.259Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06141447"
    },
    {
      "nct_id": "NCT03555838",
      "title": "Combined Robotic Training and tDCS in Chronic SCI",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Spinal Cord Injuries",
        "Tetraplegia"
      ],
      "interventions": [
        {
          "name": "transcranial direct current stimulation",
          "type": "OTHER"
        },
        {
          "name": "sham transcranial direct current stimulation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Burke Medical Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 13,
      "start_date": "2017-05-01",
      "completion_date": "2023-12-01",
      "has_results": false,
      "last_update_posted_date": "2022-03-02",
      "last_synced_at": "2026-10-24T09:23:26.259Z",
      "location_count": 1,
      "location_summary": "White Plains, New York",
      "locations": [
        {
          "city": "White Plains",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03555838"
    },
    {
      "nct_id": "NCT03137407",
      "title": "Phase 2 DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Plantar Fasciitis"
      ],
      "interventions": [
        {
          "name": "Botulinum Toxins, Type A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Revance Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 59,
      "start_date": "2017-06-12",
      "completion_date": "2018-02-20",
      "has_results": true,
      "last_update_posted_date": "2023-09-18",
      "last_synced_at": "2026-10-24T09:23:26.259Z",
      "location_count": 5,
      "location_summary": "Duluth, Georgia • Des Plaines, Illinois • Overland Park, Kansas + 2 more",
      "locations": [
        {
          "city": "Duluth",
          "state": "Georgia"
        },
        {
          "city": "Des Plaines",
          "state": "Illinois"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03137407"
    },
    {
      "nct_id": "NCT00901407",
      "title": "Lamotrigine Augmentation in Resistant Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Unipolar Depression"
      ],
      "interventions": [
        {
          "name": "lamotrigine",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "paroxetine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Louisiana State University Health Sciences Center in New Orleans",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 138,
      "start_date": "2003-12",
      "completion_date": "2007-04",
      "has_results": false,
      "last_update_posted_date": "2009-05-13",
      "last_synced_at": "2026-10-24T09:23:26.259Z",
      "location_count": 1,
      "location_summary": "New Orleans, Louisiana",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00901407"
    },
    {
      "nct_id": "NCT00511836",
      "title": "ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Alcohol Dependence"
      ],
      "interventions": [
        {
          "name": "VIVITROL 380 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alkermes, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 31,
      "start_date": "2007-07",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2017-07-11",
      "last_synced_at": "2026-10-24T09:23:26.259Z",
      "location_count": 1,
      "location_summary": "Belmont, Massachusetts",
      "locations": [
        {
          "city": "Belmont",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00511836"
    },
    {
      "nct_id": "NCT01971164",
      "title": "Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anemia of Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "JTZ-951",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akros Pharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 29,
      "start_date": "2013-05",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2014-07-14",
      "last_synced_at": "2026-10-24T09:23:26.259Z",
      "location_count": 5,
      "location_summary": "Lakewood, Colorado • Miami, Florida • Orlando, Florida + 2 more",
      "locations": [
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01971164"
    },
    {
      "nct_id": "NCT01107964",
      "title": "Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dry Eye Syndrome"
      ],
      "interventions": [
        {
          "name": "Oral Omega-3-acid ethyl esters",
          "type": "DRUG"
        },
        {
          "name": "Placebo corn oil capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2010-07",
      "completion_date": "2015-06-15",
      "has_results": true,
      "last_update_posted_date": "2017-12-22",
      "last_synced_at": "2026-10-24T09:23:26.259Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01107964"
    }
  ]
}